Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey

Lee A. Richter, Jim Han, Sarah Bradley, Filipa C. Lynce, Shawna C. Willey, Eshetu Tefera, Craig Pollack

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: The aim of the study was to evaluate knowledge, attitudes, and practice patterns of physicians prescribing topical estrogen for women with urogenital atrophy and a history of breast cancer. METHODS: A cross-sectional survey of breast surgeons, urogynecologists, and gynecologists was distributed via their professional societies: the American Society of Breast Surgeons (ASBrS), the American Urogynecologic Society (AUGS), and the Society of Gynecologic Surgeons (SGS). Providers reported level of comfort prescribing vaginal estrogen for urogenital symptoms for women with different categories of breast cancer and current treatment: estrogen receptor (ER) negative, ER positive no longer on endocrine therapy, and ER positive currently on adjuvant endocrine therapy. General knowledge questions assessed agreement on a 5-point Likert scale to statements about vaginal estrogen safety and pharmacology. RESULTS: A total of 820 physicians completed the survey: 437 responses from the ASBrS (response rate, 26.7%), 196 from AUGS (15%), and 187 from SGS (44.5%). The majority of physicians (84%), regardless of specialty, felt comfortable prescribing vaginal estrogen to women with a history of ER-negative cancer: 65.7% felt comfortable prescribing for women with ER-positive breast cancer no longer on endocrine therapy; 51.3% for women on an aromatase inhibitor; and 31.4% for women on tamoxifen. Urogynecologists were significantly more comfortable than breast surgeons prescribing vaginal estrogen for the lowest risk patients, whereas breast surgeons had the highest level of comfort for women currently on endocrine therapy. CONCLUSIONS: This study highlights heterogeneity in practice patterns both within and across specialties. The clinical variation seen in this study suggests providers may benefit from increased knowledge regarding vaginal estrogen.

Original languageEnglish (US)
Pages (from-to)714-719
Number of pages6
JournalMenopause (New York, N.Y.)
Volume26
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Atrophy
Estrogens
Breast Neoplasms
Estrogen Receptors
Breast
Physicians' Practice Patterns
Physicians
Health Knowledge, Attitudes, Practice
Therapeutics
Aromatase Inhibitors
Tamoxifen
Surveys and Questionnaires
Cross-Sectional Studies
Surgeons
Pharmacology
Safety
Neoplasms

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer : results of a national provider survey. / Richter, Lee A.; Han, Jim; Bradley, Sarah; Lynce, Filipa C.; Willey, Shawna C.; Tefera, Eshetu; Pollack, Craig.

In: Menopause (New York, N.Y.), Vol. 26, No. 7, 01.07.2019, p. 714-719.

Research output: Contribution to journalArticle

Richter, Lee A. ; Han, Jim ; Bradley, Sarah ; Lynce, Filipa C. ; Willey, Shawna C. ; Tefera, Eshetu ; Pollack, Craig. / Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer : results of a national provider survey. In: Menopause (New York, N.Y.). 2019 ; Vol. 26, No. 7. pp. 714-719.
@article{b5dfe24336bb4efea70de3aea29ca703,
title = "Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer: results of a national provider survey",
abstract = "OBJECTIVE: The aim of the study was to evaluate knowledge, attitudes, and practice patterns of physicians prescribing topical estrogen for women with urogenital atrophy and a history of breast cancer. METHODS: A cross-sectional survey of breast surgeons, urogynecologists, and gynecologists was distributed via their professional societies: the American Society of Breast Surgeons (ASBrS), the American Urogynecologic Society (AUGS), and the Society of Gynecologic Surgeons (SGS). Providers reported level of comfort prescribing vaginal estrogen for urogenital symptoms for women with different categories of breast cancer and current treatment: estrogen receptor (ER) negative, ER positive no longer on endocrine therapy, and ER positive currently on adjuvant endocrine therapy. General knowledge questions assessed agreement on a 5-point Likert scale to statements about vaginal estrogen safety and pharmacology. RESULTS: A total of 820 physicians completed the survey: 437 responses from the ASBrS (response rate, 26.7{\%}), 196 from AUGS (15{\%}), and 187 from SGS (44.5{\%}). The majority of physicians (84{\%}), regardless of specialty, felt comfortable prescribing vaginal estrogen to women with a history of ER-negative cancer: 65.7{\%} felt comfortable prescribing for women with ER-positive breast cancer no longer on endocrine therapy; 51.3{\%} for women on an aromatase inhibitor; and 31.4{\%} for women on tamoxifen. Urogynecologists were significantly more comfortable than breast surgeons prescribing vaginal estrogen for the lowest risk patients, whereas breast surgeons had the highest level of comfort for women currently on endocrine therapy. CONCLUSIONS: This study highlights heterogeneity in practice patterns both within and across specialties. The clinical variation seen in this study suggests providers may benefit from increased knowledge regarding vaginal estrogen.",
author = "Richter, {Lee A.} and Jim Han and Sarah Bradley and Lynce, {Filipa C.} and Willey, {Shawna C.} and Eshetu Tefera and Craig Pollack",
year = "2019",
month = "7",
day = "1",
doi = "10.1097/GME.0000000000001311",
language = "English (US)",
volume = "26",
pages = "714--719",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Topical estrogen prescribing patterns for urogenital atrophy among women with breast cancer

T2 - results of a national provider survey

AU - Richter, Lee A.

AU - Han, Jim

AU - Bradley, Sarah

AU - Lynce, Filipa C.

AU - Willey, Shawna C.

AU - Tefera, Eshetu

AU - Pollack, Craig

PY - 2019/7/1

Y1 - 2019/7/1

N2 - OBJECTIVE: The aim of the study was to evaluate knowledge, attitudes, and practice patterns of physicians prescribing topical estrogen for women with urogenital atrophy and a history of breast cancer. METHODS: A cross-sectional survey of breast surgeons, urogynecologists, and gynecologists was distributed via their professional societies: the American Society of Breast Surgeons (ASBrS), the American Urogynecologic Society (AUGS), and the Society of Gynecologic Surgeons (SGS). Providers reported level of comfort prescribing vaginal estrogen for urogenital symptoms for women with different categories of breast cancer and current treatment: estrogen receptor (ER) negative, ER positive no longer on endocrine therapy, and ER positive currently on adjuvant endocrine therapy. General knowledge questions assessed agreement on a 5-point Likert scale to statements about vaginal estrogen safety and pharmacology. RESULTS: A total of 820 physicians completed the survey: 437 responses from the ASBrS (response rate, 26.7%), 196 from AUGS (15%), and 187 from SGS (44.5%). The majority of physicians (84%), regardless of specialty, felt comfortable prescribing vaginal estrogen to women with a history of ER-negative cancer: 65.7% felt comfortable prescribing for women with ER-positive breast cancer no longer on endocrine therapy; 51.3% for women on an aromatase inhibitor; and 31.4% for women on tamoxifen. Urogynecologists were significantly more comfortable than breast surgeons prescribing vaginal estrogen for the lowest risk patients, whereas breast surgeons had the highest level of comfort for women currently on endocrine therapy. CONCLUSIONS: This study highlights heterogeneity in practice patterns both within and across specialties. The clinical variation seen in this study suggests providers may benefit from increased knowledge regarding vaginal estrogen.

AB - OBJECTIVE: The aim of the study was to evaluate knowledge, attitudes, and practice patterns of physicians prescribing topical estrogen for women with urogenital atrophy and a history of breast cancer. METHODS: A cross-sectional survey of breast surgeons, urogynecologists, and gynecologists was distributed via their professional societies: the American Society of Breast Surgeons (ASBrS), the American Urogynecologic Society (AUGS), and the Society of Gynecologic Surgeons (SGS). Providers reported level of comfort prescribing vaginal estrogen for urogenital symptoms for women with different categories of breast cancer and current treatment: estrogen receptor (ER) negative, ER positive no longer on endocrine therapy, and ER positive currently on adjuvant endocrine therapy. General knowledge questions assessed agreement on a 5-point Likert scale to statements about vaginal estrogen safety and pharmacology. RESULTS: A total of 820 physicians completed the survey: 437 responses from the ASBrS (response rate, 26.7%), 196 from AUGS (15%), and 187 from SGS (44.5%). The majority of physicians (84%), regardless of specialty, felt comfortable prescribing vaginal estrogen to women with a history of ER-negative cancer: 65.7% felt comfortable prescribing for women with ER-positive breast cancer no longer on endocrine therapy; 51.3% for women on an aromatase inhibitor; and 31.4% for women on tamoxifen. Urogynecologists were significantly more comfortable than breast surgeons prescribing vaginal estrogen for the lowest risk patients, whereas breast surgeons had the highest level of comfort for women currently on endocrine therapy. CONCLUSIONS: This study highlights heterogeneity in practice patterns both within and across specialties. The clinical variation seen in this study suggests providers may benefit from increased knowledge regarding vaginal estrogen.

UR - http://www.scopus.com/inward/record.url?scp=85069236175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069236175&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000001311

DO - 10.1097/GME.0000000000001311

M3 - Article

C2 - 30939535

AN - SCOPUS:85069236175

VL - 26

SP - 714

EP - 719

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 7

ER -